Presentation
250mg/5mL ampoule
SAS
Role
Management of patients with severe heavy metal poisoning (e.g. arsenic, mercury or lead) where parenteral therapy is required.
All cases should be discussed with a clinical toxicologist through local toxicology service or Poisons Information Centre 13 11 26.
Dose
Give 5mg/kg IV q8h on advice from a clinical toxicologist.
Stocking recommendations
| Tertiary centre | Regional centre | Rural centre | Remote centre |
|---|---|---|---|
| 0 – 10 ampoules | 0 ampoules | 0 ampoules | 0 ampoules |
Rationale
Parenteral heavy metal chelation is rarely required. Of the available parenteral chelators, DMPS has the best safety profile. The current stocking recommendations reflect a pragmatic approach to antidote availability. DMPS is not registered for use in Australia but is available via the Special Access Scheme.
Disclaimer
Fact sheet developed by Queensland Poisons Information Centre.
This fact sheet is about the use of these antidotes in Australia, and may not apply to other countries. Children’s Health Queensland Hospital and Health Service cannot be held responsible for the accuracy of information, omissions of information, or any actions that may be taken as a consequence of reading this fact sheet.